84. サルコイドーシス Sarcoidosis Clinical trials / Disease details
臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05689879 (ClinicalTrials.gov) | February 7, 2023 | 2/5/2022 | Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis | Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis : a Prospective, Randomized, Controlled Trial | Sarcoidosis | Drug: STOP arm | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | N/A | All | 90 | Phase 3 | NULL |
| 2 | NCT03704610 (ClinicalTrials.gov) | March 28, 2019 | 10/10/2018 | Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES) | Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES STUDY) | Extrathoracic Sarcoidosis | Drug: Infliximab;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | N/A | All | 31 | Phase 3 | France |
| 3 | EUCTR2014-002224-26-NL (EUCTR) | 07/05/2015 | 03/02/2015 | Infliximab dosing based on blood concentrations in patients with sarcoidosis: smart dosing | A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment - Concentration guided dosing of infliximab in sarcoidosis | Sarcoidosis;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Remicade Product Name: Remicade | St. Antonius Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | ||||
| 4 | EUCTR2011-003630-13-NL (EUCTR) | 22/11/2011 | 07/11/2011 | Tracer for the imaging of disease activity in sarcoidosis in the lung | 99mTc labelled anti-TNF-alpha for the imaging of disease activity in pulmonary sarcoidosis - TISS | Pulmonary sarcoidosis MedDRA version: 17.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: 99mTc-Infliximab Product Code: not applicable INN or Proposed INN: not applicable Other descriptive name: 99m technetium infliximab | Sint Antonius Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | ||||
| 5 | NCT00073437 (ClinicalTrials.gov) | October 2003 | 20/11/2003 | A Study of Infliximab in Patients With Sarcoidosis | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade?) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement. | Sarcoidosis | Drug: Infliximab | Centocor, Inc. | NULL | Completed | 18 Years | N/A | Both | 139 | Phase 3 | United States;Austria;Belgium;France;Germany;Netherlands;Sweden;Switzerland;United Kingdom;Italy |